Potential compound from herbal food of Rhizoma Polygonati for treatment of COVID-19 analyzed by network pharmacology: Viral and cancer signaling mechanisms

Journal of Functional Foods

Yifan Sheng¹  Xugang Li²  Qian Wang³  Chenglin Mu⁴  Yingqiu Xie⁴  Amr Amin⁵ 

[1] Sino-German Joint Research Center for Agricultural Biology, College of Life Sciences, Shandong Agricultural University, Daizong Street 61, Tai'an 271018, China;Biology Department, UAE University, Al Ain 15551, United Arab Emirates;College of Life Science, Northeast Agricultural University, Harbin 150030, China;State Key Laboratory of Crop Biology, College of Life Sciences, Shandong Agricultural University, Daizong Street 61, Tai'an 271018, China;Tai'an Xianlu Food Co. Ltd., Tai'an, China;

关键词: Network pharmacology;    Rhizoma polygonati;    Molecular docking;    New coronavirus pneumonia;    COVID-19;   

DOI  :  

来源: DOAJ

【 摘 要 】

Rhizoma Polygonati (huangjing in Chinese, 黄精) is a medicine food homology herb used as a component of traditional Chinese medicine treating COVID-19 in the current pandemic emergency in China but the mechanisms remain elusive. Here using TCMSP and Swiss Target Prediction databases to sort out the potential targets of the main chemical components and GenCLiP3, NCBI, and GeneCard databases to search for COVID-19 related targets, the chemical compound-target-pathway network was analyzed. Each component was molecularly docked with host cell target angiotensin converting enzyme II, SARS-CoV-2 targets Spike protein, RNA-dependent RNA polymerase, or 3CL hydrolase. Our results showed a higher affinity of the compound diosgenin and (+)-Syringaresinol-O-beta-D-glucoside binding to the three SARS-CoV-2 proteins compared to the other compounds tested. Thus, our data suggest that potential compounds in Rhizoma Polygonati may act on different targets with viral and cancer related signaling and have a great potential in treatment of COVID-19.

【 授权许可】

Unknown